Outlook Therapeutics’ Bevacizumab Formulation Fails Primary Endpoint in nAMD Trial
ONS-5010 did not demonstrate non-inferior BCVA gains compared to ranibizumab at week 8 in the Phase III NORSE EIGHT trial. …
Wet AMD Challenges and Breakthroughs at APVRS 2024
The 17th Congress of the Asia-Pacific Vitreo-retina Society (APVRS 2024) kicked off with a series of engaging discussions on the…
latest posts
